Skip to main content
PeerJ logoLink to PeerJ
. 2023 Jan 5;11:e14399. doi: 10.7717/peerj.14399

Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: a literature review

Faviola Tavares-Carreon 1,, Karla De Anda-Mora 2, Idalia C Rojas-Barrera 3,4, Angel Andrade 2
Editor: Jack Leo
PMCID: PMC9826615  PMID: 36627920

Abstract

Serratia marcescens is a ubiquitous bacterium from order Enterobacterales displaying a high genetic plasticity that allows it to adapt and persist in multiple niches including soil, water, plants, and nosocomial environments. Recently, S. marcescens has gained attention as an emerging pathogen worldwide, provoking infections and outbreaks in debilitated individuals, particularly newborns and patients in intensive care units. S. marcescens isolates recovered from clinical settings are frequently described as multidrug resistant. High levels of antibiotic resistance across Serratia species are a consequence of the combined activity of intrinsic, acquired, and adaptive resistance elements. In this review, we will discuss recent advances in the understanding of mechanisms guiding resistance in this opportunistic pathogen.

Keywords: Serratia marcescens, Opportunistic pathogen, Intrinsic resistance, Acquired resistance, Antimicrobial resistance

Introduction

The genus Serratia comprises ubiquitous Gram-negative rod-shaped bacteria belonging to the Enterobacterales order (Adeolu et al., 2016; Grimont, Grimont & De Rosnay, 1977). So far, 23 species are recognized within this genus, six of which have been associated with human infections, including S. marcescens, S. plymuthica, S. liquefaciens, S. rubidaea, S. odorifera, and S. fonticola. From these, S. marcescens is the species most commonly isolated (Traub, 2000). In addition, S. marcescens can infect a vast set of hosts including corals, insects, nematodes, plants, and mammals (Mahlen, 2011).

S. marcescens operates as an opportunistic pathogen mainly affecting patients with prior antibiotic treatment or hosts with a weakened immune system. S. marcescens outbreaks are frequently reported in the literature (e. g., over 100 records at the Outbreak database from 1968 to 2019 (Vonberg et al., 2011); however, the majority of infections are likely individual cases (Wisplinghoff et al., 2004). At the nosocomial setting S. marcescens infections are more frequently reported in neonatology and intensive care units (ICU), where this microorganism has been isolated from catheters, oxygenation devices, prefilled syringes, needles, parenteral solutions, milk-drawers, sinks, nails, and hands of health care workers. It has been also found in disinfectant solutions or double-distilled water, reflecting its enormous metabolic versatility and capability to adapt and survive in adverse environments (Casolari et al., 2005; Greco-Stewart et al., 2012; Redondo-Bravo et al., 2019).

Within the wide range of infections provoked by S. marcescens are found pneumonia, sepsis, meningitis, peritonitis, endocarditis, arthritis, osteomyelitis, keratitis, and urinary tract and skin infections (Fig. 1) (David et al., 2006; Korner et al., 1994; Su et al., 2003; Voelz et al., 2010). Clinical management of S. marcescens infections is challenging due to its intrinsic resistance to different classes of antibiotics such as ampicillin, first and second generation cephalosporins, macrolides, and cationic antimicrobial peptides (CAPs) (Ball, McGhie & Geddes, 1977; Evans, Feola & Rapp, 1999). Accordingly, patients in ICU under antibiotic regimen can be considered at higher risk to develop infections by this bacterium.

Figure 1. S. marcescens, beneficial and pathogenic effects.

Figure 1

S. marcescens is distributed worldwide and it has positive environmental effects, it can produce antimicrobial compounds such as prodigiosin, as well as factors that promote plant growth. Some member of Serratia genus can degrade a wide variety of compounds including chitin and pollutants as heavy metals, therefore they can be considered as biological control agents. In counterpart, a significant phytosanitary risk can be associated to S. marcescens, based on its potential to damage several crops, including cucurbits, maize, pepper, sunflower, among others. This bacterium is particularly relevant as an opportunistic human pathogen displaying multi-resistant against several classes of antibiotics.

The infections by S. marcescens are commonly treated with cefepime or carbapenems (Siedner et al., 2014; Tamma et al., 2022). In addition, most S. marcescens isolates are found susceptible to the aminoglycoside amikacin, however recent reports indicate an increasing resistance to gentamicin and tobramycin (Bertrand & Dowzicky, 2012; Sader et al., 2014). In fact, current emergence of multi-resistant isolates has narrowed the therapeutic options against this pathogen, situation that has been recently alerted by the WHO WHO, 2017.

Bacterial exposure to antibiotics is considered a main factor leading to resistant phenotypes. Nonetheless, a recent analysis of S. marcescens isolates responsible for an outbreak in 1969 in a Spanish neonatal intensive care unit revealed the presence of resistance genes toward antibiotics and disinfectants non commercialized by the time of their original isolation (Saralegui et al., 2020). Also, a comparison between strains collected during the 1940s and the beginning of the twenty-first centuries indicated that resistance to different classes of antibiotics already existed in ancient S. marcescens isolates (Fuste et al., 2012), pointing out existence of additional factors unrelated to drug therapy driving evolution of such genes.

In this scenario, a recent analysis of 32 Serratia spp. genomes led to the conclusion that environmental strains represent an underestimated reservoir for antibiotic resistance determinants (Sandner-Miranda et al., 2018), suggesting that antibiotic resistance genes (ARG) in this genus are inherently encoded. And despite, 76.5% of annotated Serratia genomes correspond to clinical isolates, they seem to encode a comparable number of ARG as environmental Serratia strains (Sandner-Miranda et al., 2018).

Antimicrobial resistance mechanisms can be classified as intrinsic, acquired, or adaptive (Fig. 2). Intrinsic resistance refers to the inherent properties of a microorganism that limit the action of antimicrobials e.g., decreased membrane permeability and active efflux of toxic compounds. Acquired resistance might occur due to acquisition of ARG, most commonly through plasmid horizontal gene transfer, or as result of gene mutations. Lastly, adaptive resistance, also called phenotypic resistance, is linked to expeditious transcriptome adjusting in response to stress conditions or environmental stimuli (Hasan, Dutta & Nguyen, 2021). Contrary to intrinsic or acquired resistance, adaptive resistance is a non-inheritable phenotype that generally reverts upon removal of the triggering signal. In S. marcescens temperature, pH, oxidative stress, and exposure to disinfectants have been linked with gene regulation and higher bacterial survival (Begic & Worobec, 2008; de Ondarza, 2017; Maseda et al., 2009). Nonetheless, adaptive phenotypes are still modestly understood in the context of antibiotic resistance. Thus, in this review we will focus on the current understanding of intrinsic and acquired mechanisms guiding S. marcescens multi-resistance.

Figure 2. Mechanisms of antibiotic resistance in S. marcescens can be divided as intrinsic, acquired, and adaptive resistance.

Figure 2

S. marcescens intrinsic resistance is related with ARG inherently found in the chromosome (e.g., β-lactamases and efflux pumps), along with lipopolysaccharide (LPS) modifications (pale green rectangle). Acquired resistance is associated with HGT, genetic material transfer between species could derivate in antibiotic resistance and propagation of such phenotype beyond interspecies (lime green square). Adaptive resistance often arises due to pressures from the ecological niche inducing changes in cell permeability and biofilm formation (dark green square). Concerted activity of these mechanisms migth lead in synergistic drug resistance in S. marcescens. Each antibiotic resistance mechanisms is discussed in the appropriate subsection of this review.

Survey methodology

Primary and secondary literature relevant to the topic of this review was assessed using PubMed (MeSH), MedLine, Google Scholar, and Web of Science using the search terms for articles and their combinations in English to search: “Serratia”, “Serratia marcescens”, “Entereobacterials”, “Serratia infections” in combination with, “diseases outbreak”, “efflux pumps”, “AmpC”, “beta-lactamase”, “carbapenemase”, “lipopolysaccharides”, “beta-lactam plasmids”, “gene flow”, “horizontal gene transfer”, “antimicrobial resistance”, “antibacterial agents”, “resistance genes”, “antibiotics adaptation”, “heavy metals”, “genomic evolution”, “pollution”, “stress responses”, “cryptic genes”, “evolution”, ”experimental evolution”, along with using “+”, “AND”, and “OR” for a specific search result. The identified articles were initially checked to determine their appropriateness to the subject, and all the relevant articles were read in detail. Clinical studies were excluded from the search results. Earlier literature reviews on the same topic were consulted to ensure key topics were not missed (Mahlen, 2011; Sanchez et al., 1997).

Intrinsic resistance of S. marcescens efflux pumps and antimicrobial resistance

Efflux pumps are transmembrane proteins that regulate the extrusion of toxic components from the bacterial intracellular to the external environment (Blanco et al., 2016). Efflux pumps are able to recognize a diverse set of hazardous compounds including detergents, fatty acids, heavy metals, bile salts, dyes, and antibiotics (Marquez, 2005). Therefore, efflux pumps are among the most important contributors to intrinsic resistance phenotypes (Hernando-Amado et al., 2016). In addition, gene mutations might modify the efflux pump substrate specificity leading to acquired drug resistance (Blair et al., 2015).

Six families of efflux pumps have been described, from these the (i) ATP-binding cassette (ABC) transporters family, couples the energy derived from ATP hydrolysis to compound extrusion. In contrast, the (ii) major facilitator superfamily (MFS), (iii) small multidrug resistance (SMR), (iv) multidrug and toxic compound extrusion (MATE), (v) resistance/nodulation/cell division (RND) superfamily, and (vi) proteobacterial antimicrobial compound efflux (PACE) families operate as chemiosmotic coupling secondary active transporters powered by electrochemical ion gradients (Blanco et al., 2016; Du et al., 2018).

Genomic analysis revealed over 70 different efflux-associated genes broadly distributed among nosocomial and environmental Serratia isolates (Sandner-Miranda et al., 2018). This suggests that the origin and spread of a considerable set of these Serratia efflux genes ensued independently of exposure to antimicrobials, either in clinical or agricultural contexts.

Homologous genes of potential efflux systems have been found encoded within S. marcescens genomes (Iguchi et al., 2014; Sandner-Miranda et al., 2018) comprising representatives of five out of the six families: ABC, MATE, MFS, SMR, and RDN. The PACE family is the only one absent from sequenced Serratia strains (Table 1). In addition, representative members of the ABC, RDN, SMR and MFS efflux pumps have been implicated with multidrug resistance. Nonetheless, contribution of S. marcescens homologous genes of MATE efflux systems has not been evaluated yet.

Table 1. Characterized efflux systems of S. marcescens.

Family Efflux system Antibiotic resistance Xenobiotic resistance Reference
ABC SmdAB Norfloxacin
Tetracycline
TPPCl
DAPI
Matsuo et al. (2008)
MacAB Aminoglycosides
Polymyxin
ND Shirshikova et al. (2021)
RND SdeXY Tigecycline
Tetracycline
Ciprofloxacin
Cefpirome
Oxacillin
Erythromycin
Novobiocin
SDS
Bile Salts
Hornsey et al. (2010) and Toba et al. (2019)
SdeCDE Novobiocin ND Begic & Worobec (2008)
SdeAB Fluoroquinolones Chloramphenicol Novobiocin SDS
EtBr
Kumar & Worobec (2005)
SdeGH and SdePQ-OmsA Novobiocin Benzalkonium Chloride
Triclosan
SDS
Deoxycholate
EtBr
Toba et al. (2019)
SdeIJ ND Benzalkonium Chloride Toba et al. (2019)
SMR SsmE Norfloxacin Acriflavine
EtBr
Minato et al. (2008)
SsmD ND ND Minato et al. (2008)
MFS SmfY Norfloxacin Benzalkonium Chloride Acriflavine
EtBr
TPPCl
Methyl Viologen
Hoechst 33342
Shahcheraghi et al. (2007)
SmvA ND Chlorhexidine
Octenidine
Cationic Biocides
Wand et al. (2019)
TetA Tetracycline ND Thompson et al. (2007)

Notes.

TPPCl
tetraphenylphosphonium chloride
DAPI
4′,6-diamidino-2-phenylindole
SDS
sodium dodecyl sulphate
EtBr
Ethidium bromide
ND
Not determined

ATP-driven efflux pumps (ABC)

The ABC transporters compose a diverse family of efflux pumps characterized for the presence of nucleotide-binding domains (NBDs) along to transmembrane domains (TMDs) (Dawson & Locher, 2006). The ATP binding/hydrolysis by the NBDs drives conformational changes that alternate between an inward-open and outward-open conformation to translocate substrates across the membrane (Choudhury et al., 2014). SmdAB (homolog to MdlAB of E. coli) was the first ABC efflux pump described in a clinical strain of S. marcescens. Mobilization of a plasmid expressing mdAB into the hyper-sensitive E. coli KAM32 conferred resistance to norfloxacin, tetracycline, tetraphenylphosphonium chloride (TPPCl) and 4′,6-diamidino-2-phenylindole (DAPI) (Matsuo et al., 2008).

MacAB (a canonical ABC-type efflux pump) has been linked to macrolide resistance in different Enterobacteriaceae members. However, in S. marcescens SM6 deletion of macAB did not impact to erythromycin sensitivity, instead the macAB strain was significantly more sensitive to aminoglycosides and to the CAPs colistin and polymyxin B (Shirshikova et al., 2021). Since S. marcescens is intrinsically resistant to this class of antimicrobials (as described below) the phenotype displayed by the macAB strain is intriguing. Nonetheless, in Stenotrophomonas maltophilia the MacAB homolog has also been implicated with extrusion of polymyxins, aminoglycosides and macrolides (Lin et al., 2014b). Notably, MacAB in S. marcescens SM6 was shown to be essential for survival during oxidative stress, also to contribute during biofilm formation and bacterial motility (Shirshikova et al., 2021), making this efflux pump an attractive target to reduce bacterial pathogenicity as well as antimicrobial resistance.

Electrochemical gradient-driven efflux pumps (RND, SMR and MFS)

RND efflux pump family has been characterized widely in Gram negative bacteria; they consist of tripartite complexes composed by the inner membrane RND pump with 12 transmembrane regions; the periplasmic adaptor protein which connect the pump to the outer-membrane protein (OMP) responsible to assemble an OM conduit (Venter et al., 2015). The RND pump is responsible for drug selectivity and operates as an antiporter coupling drug/H+ transport. RND efflux pumps in E. coli incorporate TolC as the OMP (Nishino et al., 2003), however HasF is reported as the OMP mainly associated to the RND efflux pumps in S. marcescens (Hornsey et al., 2010).

The best characterized RND efflux pumps of S. marcescens are SdeXY (Chen et al., 2003a), SdeCDE, and SdeAB (Kumar & Worobec, 2005). SdeXY was the first multidrug efflux pump characterized in this bacterium and it is described as a major contributor to S. marcescens intrinsic multidrug resistance (Chen et al., 2003b). Inactivation of sdeXY in the environmental strain NCTC10211 leads to an increased susceptibly to tigecycline, tetracycline, ciprofloxacin, and cefpirome (Hornsey et al., 2010). Similarly, deletion of sdeXY in S. marcescens Db10 conferred a significant reduction of MIC values to a broad spectrum of antimicrobial agents, including oxacillin, erythromycin, novobiocin, SDS, bile salts, among others (Toba et al., 2019). Moreover, up-regulation of sdeXY has been noticed in a clinical S. marcescens strain resistant to tigecycline (Hornsey et al., 2010). SdeAB efflux pump is considered to play a major role in S. marcescens multidrug resistance, it is implicated in extrusion of a wide range of compounds including fluoroquinolones, chloramphenicol, novobiocin, sodium dodecyl sulphate, and ethidium bromide (Kumar & Worobec, 2005). Gene deletion of sdeB in the clinical S. marcescens T-86 strain results in a multi-drug hyper-susceptibility phenotype. However, conflicting data indicate that the SdeAB substrate selectivity, expression, and contribution to drug resistance, is more likely strain specific (Begic & Worobec, 2008). Opposite to SdeXY and SdeAB, the SdeCDE efflux pump did not confer a multidrug resistance phenotype. SdeCDE activity has only been linked to novobiocin resistance (Begic & Worobec, 2008). A similar condition has been reported to the RND efflux pumps MdtABCD and MuxABC from E. coli and P. aeruginosa, respectively (Baranova & Nikaido, 2002; Mima et al., 2009).

Three additional RND efflux pumps SdeGH, SdeIJ, and SdePQ-OmsA have been identified in S. marcescens Db10 genome. SdeGH and SdePQ-OmsA were characterized as broad substrate specificities able to extrude benzalkonium chloride, triclosan, novobiocin, SDS, deoxycholate and ethidium bromide, whilst SdeIJ efflux pump only confers benzalkonium chloride resistance (Toba et al., 2019).

The SMR family is another efflux system conferring intrinsic resistance in Serratia genus. The SMR family is composed of small proteins (∼110 residues) which structure four transmembrane helices and operates as homodimers or heterodimers. SMR proteins extrude toxic compounds from the cytoplasm into the periplasmic space, consequently RND efflux pumps can complete the expulsion of toxic substances out of the cell (Tal & Schuldiner, 2009). In E. coli and Salmonella, SMR pumps confer resistance to a wide variety of antibiotics such as β-lactams, erythromycin, and tetracyclines, and to several quaternary ammonium compounds, such as benzalkonium chloride (Gadea et al., 2017). Nevertheless, in S. marcescens contribution of SMR to antibiotic resistance has been poorly investigated. SsmE was the first SMR efflux pump characterized in S. marcescens, it can extrude norfloxacin, acriflavine, and ethidium bromide (Minato et al., 2008) such substrate selectivity of SsmE is also conserved by its homologue EmrE, from E. coli (Minato et al., 2008). Another two SMR efflux pumps identified in S. marcescens are SsmD and SsmK, they are homologues to E. coli SugE and YdgE pumps, respectively, however they did not increase resistance to antimicrobial agents such as tetracycline, fluoroquinolones, aminoglycoside and topical antiseptics and their participation in the extrusion of xenobiotics has not been clarified (Minato et al., 2008).

On the other hand, the MFS family is the largest among the efflux pumps transporters, their members are well conserved in all phyla including bacteria, fungi, plants, and mammals (Pao, Paulsen & Saier Jr, 1998). Most MFS proteins operate as monomeric units (from 400–600 residues) with 12–14 transmembrane helices. In Gram negative bacteria the MFS transporters can be found as single proteins within the inner membrane also as part of tripartite efflux pumps (similar to RND pumps) (Neuberger, Du & Luisi, 2018). In S. marcescens Db11 the MFS efflux SmfY, was shown to confer resistance to several compounds such as norfloxacin, benzalkonium chloride, acriflavine, ethidium bromide, tetraphenylphosphonium chloride (TPPCl), methyl viologen and Hoechst 33342 (Shahcheraghi et al., 2007). SmvA (an SmfY homologous) encoded by K. pneumoniae and other Enterobacteriaceae (e.g., Salmonella, Citrobacter, and Enterobacter) has been also shown to promote efflux of chlorhexidine, octenidine and other cationic biocides Wand et al., 2019.

In the environmental isolate S. marcescens FMC 1-23-O the MFS TetA was identified as a tetracycline resistant determinant (Thompson et al., 2007). The tetracycline-responsive repressor TetR is found encoded adjacently to tetA. In absence of stimuli TetR operates as a tetA repressor, however when there is intracellular tetracycline, antibiotic binding by TetR reduces its affinity for DNA, relieving tetA expression (Thompson et al., 2007). S. marcescens encodes some other MFS pumps yet to be characterized.

Lipopolysaccharide modifications

S. marcescens as a Gram negative bacterium shows a low permeability due to the presence of its outer cell membrane. This structure confers a high rigidity that slows the passive diffusion of hydrophobic antibiotics like CAPs, which are amphiphilic short peptides produced by different species (including humans), that are able to interact and disrupt microbial membranes. Among the better characterized are found the group of polymyxins produced by Paenibacillus polymyxa (Velkov et al., 2016): polymyxin A and polymyxin E (called colistin) are used in clinical practices to treat extensively drug resistant Gram negative bacteria when other less toxic antibiotics (like carbapenems) are not an option (Tamma et al., 2022). CAPs interact with the lipopolysaccharide (LPS) molecule, displacing and disrupting Mg2+ cross bridges between anionic LPS molecules in the outer leaflet of the outer membrane, leading to cell envelope destabilization and cell death.

LPS is composed by lipid A, a core oligosaccharide (OS), and the O-antigen (O-Ag). Chemical modifications in the lipid A or into the core OS by adding positively charged substituents is associated with bacterial resistance to CAPs (Baron et al., 2016; Olaitan, Morand & Rolain, 2014b; Peschel, 2002). Particularly, LPS modification with 4-amino-4-deoxy-l-arabinose (L-Ara4N) moiety confers a net positive charge to bacterial surface which significantly reduces its affinity for polymyxins. In S. marcescens l- Ara4N is added to the lipid A, but also to the terminal d-glycero-d-talo-2-octulosonic acid (Ko) of the core OS (Vinogradov et al., 2006). LPS modification in S. marcescens occurs naturally making this bacterium intrinsically resistant to CAPs. Biosynthesis and addition of L-Ara4N to LPS requires the coordinated activation of arnBCADTEF operon, whose products mediate the synthesis and transfer of L-Ara4N to lipid A and core OS. Deletion of arnB and arnC genes in S. marcescens provoke a 1024-fold reduction on the MIC for polymyxin B (Lin et al., 2014a).

Expression of S. marcescens arn operon mainly responds to the two-component system (TCS) PhoP/PhoQ. Activation of PhoQ can be triggered through different stimuli including low Mg2+, acidic pH or polymyxin B. Accordingly, PhoQ becomes autophosphorylated then it transfers the phosphate moiety to PhoP, the phosphorylated PhoP binds directly to S. marcescens arn promoter operating as a positive transcriptional regulator (Barchiesi et al., 2012). Conservation of the PhoP binding site within the arn promoter across Serratia species suggest an important role of the PhoP/PhoQ-regulated arn pathway and LPS modification in this genus.

S. marcescens arn operon is also under the control of a second TCS, PmrA/PmrB. The activation of PmrA/PmrB system depends on a small protein called PmrD which is activated by the PhoP/PhoQ system. Thus, PmrD is a connector protein that links both regulatory systems, PhoP-PhoQ and PmrA-PmrB. Phosphorylated PmrA also recognizes arn promoter region and promotes RNA polymerase recruitment and transcription of the arn operon (Gunn et al., 1998).

The S. marcescens phoP/phoQ operon is positively auto-regulated, phosphorylated PhoP stimulates its expression by recognition of a regulatory site within phoP, however in absence of stimuli, phoPQ operon is expressed at basal levels from a constitutive promoter. In addition, the small regulatory transmembrane protein MgrB operates as a negative regulator of the PhoP/PhoQ system, disruption of mgrB result in arn overexpression (Olaitan et al., 2014a). Since deletion of regulatory proteins or TCS encoding genes retains low levels of arn expression, is considered that some other mechanisms are contributing to arn regulation in Serratia.

Chromosomally encoded antibiotic modifying enzymes

In S. marcescens like other Enterobacterales, resistance to β-lactams is mainly related to production of penicilloyl-serine transferases commonly referred as β-lactamases, including AmpC-type cephalosporinase, extended-spectrum β-lactamases (ESBL, with activity against third generation cephalosporins and aztreonam), and carbapenemases.

The chromosomally encoded Ambler class C β-lactamase, AmpC, is invariably distributed among S. marcescens sequenced isolates, its activity is linked to inducible resistance to all penicillins as well as third generation cephalosporins (Jacoby, 2009; Joris et al., 1986). Despite the low affinity and hydrolytic capability against carbapenems (even at high AmpC protein levels) the combination of porin loss (OmpF) along with AmpC over production was reported to confer resistance against meropenem in S. marcescens urine isolates from Korea (Suh et al., 2010). Stability of S. marcescens ampC transcript is conferred by an extended 5′ untranslated region of 126 nucleotides adopting a stem-loop structure (Mahlen et al., 2003).

The ampC expression is induced by some β-lactams through accumulation of cytosolic peptidoglycan catabolites, they displace UDP-acetylmuramic acid peptides from AmpR impairing its activity as transcriptional repressor (Vadlamani et al., 2015). This signaling cascade is also emulated by mutations in the N-acetylmuramyl-alanine amidase AmpD or in the membrane-bound permease AmpG (Schmidtke & Hanson, 2006).

The ampC regulatory cluster (ampD, ampE, ampR, and ampG) is found ubiquitously among S. marcescens isolates. Nevertheless, in S. marcescens mutations leading to ampC derepression are estimated to occur in-vitro at rates ∼60-fold lower compared to Citrobacter freundii or Enterobacter species (Kohlmann, Bähr & Gatermann, 2018). Accordingly, Tamma et al. (2013) tested over 300 isolates by two phenotypic methods, determined that only 15% of S. marcescens isolates were positive for high-level of AmpC production compared to 38% of Enterobacter spp. isolates. In this scenario, Choi et al. (2007) showed that 7% of S. marcescens isolates developed resistance to extended spectrum cephalosporins during on patient drug therapy. While an other study from the same medical center revealed that none of 113 patients with Serratia infections (also treated with cephalosporins) developed antibiotic resistance (Choi et al., 2008). In contrast, emergence of E. cloacae resistance during therapy with extended-spectrum cephalosporins has been documented in 8% (Choi et al., 2008), and 19% (Chow et al., 1991) of the isolates.

In addition, some mutations leading to AmpC broader activity have been described in certain S. marcescens strains. These include the amino acid substitution S220Y located at the omega loop, it maps at the bottom of the entrance to the β-lactamase active site and increases by about 100-fold the catalytic efficiency of the enzyme conferring bacterial resistance to ceftazidime (Hidri et al., 2005). A rare 12 nucleotide deletion in ampC leading to the loss of four residues from the H-10-helix was also found to confer significant hydrolysis to fourth generation cephalosporins, cefepime and cefpirome (Mammeri et al., 2004).

A mechanism for carbapenem-resistance is conferred by the chromosomal SME (S. marcescens enzyme), this enzyme is capable of hydrolyze penicillin, aztreonam, cephalosporins, and imipenem. Nonetheless, since first report of SME-1 forty years ago in London (Naas et al., 1994), S. marcescens isolates carrying this gene have been rarely reported, most of them in North America and United Kingdom (Carrer et al., 2008; Cayo et al., 2017; Gales et al., 2001; Poirel et al., 2007; Queenan et al., 2006; Queenan et al., 2000).

Regarding aminoglycoside resistance, it often arises after chemical modifications through the activity of aminoglycoside modifying enzymes (AME). Three subclasses of AME have been described: the acyl-coenzyme A-dependent N-acetyltransferases (AAC); the nucleoside triphosphate-dependent O-phosphotransferases (APH); and the nucleoside triphosphate-dependent O-nucleotidyltransferases (ANT) (Ramirez & Tolmasky, 2010). Despite genes aac(6′)-Ic and aph(3′) are commonly found within S. marcescens chromosome (Sandner-Miranda et al., 2018) most clinical isolates remain susceptible to this class of antibiotics. Accordingly, scarce mRNA levels of aac(6′)-Ic have been identified across S. marcescens strains and a large palindromic sequence overlapping the −35 region of aac(6′)-Ic may be responsible of such low expression levels (Shaw et al., 1992).

Acquired resistance

Plasmid-encoded β-lactamases

Horizontal gene transfer is a common event in prokaryotes, it allows acquisition of loci encoding potentially advantageous elements under certain conditions. In addition, integrative and conjugative elements seem to contribute to gene flow between quite distant bacterial taxa (Sheinman et al., 2021). Regardless of gene transfer mechanism β-lactamases encoding genes are among the most frequent ARG transferred between bacteria, these enzymes are divided into four classes: the class A, C, and D employ a serine residue for inactivation of the β-lactam (Lamotte-Brasseur et al., 1994), whereas class B enzymes are metallo- β-lactamases that require Zinc as a cofactor (Crowder, Spencer & Vila, 2006).

In S. marcescens and related Enterobacterales the class A, CTX-M-type (cefotaxime enzyme), SHV (sulfhydryl variable), and the KPC (K. pneumoniae carbapenemase), along with class D β-lactamases OXA (oxacillinases), represent ESBL rapidly spreading between clinical strains (Bolourchi et al., 2022; Miao et al., 2019). The first notifications on the prevalence of KPC in S. marcescens clinical isolates became available at the beginning of the twenty-first century in China, Greece, Brazil, and United States (Cai et al., 2008; Firmo et al., 2020; Sidjabat et al., 2009; Tsakris et al., 2010; Zhang et al., 2007). Remarkably, the majority of KPC-producing S. marcescens strains were isolated from patients in surgical intensive care unit (Ferreira et al., 2020), suggesting acquisition of KPC plasmid at the nosocomial environment.

Carbapenem resistant S. marcescens strains recently isolated in China have been reported to carry blaKPC-3 (Chen et al., 2022), and blaKPC-2 (Wang et al., 2022), on incompatibility (Inc) group plasmids: IncX8 and IncX6-like, respectively. Also, a set of four carbapenem resistant S. marcescens isolates from Iranians patients patients were found to carry the blaOXA-48a gene on a plasmid belonging to the mcr incompatibility group (Bolourchi et al., 2022). A related plasmid (IncL-pOXA-48a) was previously detected among carbapenem resistant S. marcescens strains from Spain (Perez-Viso et al., 2021).

A comprehensive pangenome analysis of S. marcescens isolates from 35 countries revealed a population structure comprising 12 lineages (Matteoli et al., 2021). From these, blaKPC-2 plasmid was found widely distributed across lineage Sm7 (one plasmid per genome). Lineage Sm9 showed the highest plasmid diversity (3.26 plasmids per genome on average), with some members of this clade encoding a class D β-lactamase (Matteoli et al., 2021). The mobilized colistin resistance gene mcr-9 was also detected in three strains from lineages Sm9 and Sm12 suggesting that some strains might function as reservoirs of mcr-9 plasmids.

Metallo-β-lactamases are found among the most concerning enzymes, they can hydrolyze the broadest spectrum of penicillins, and their activities are not suppressed by next-generation inhibitors, as avibactam or vaborbactam (Boyd et al., 2020). Members of this group of enzymes comprise the versatile carbapenemases IMP (imipenemase), VIM (Verona Integron-encoded metallo-β-lactamase), and NDM (New Delhi metallo- β-lactamase) they are frequently transmitted through plasmids or integrons, and their presence in S. marcescens strains has been sporadically documented all over the world (Gajdacs & Urban, 2019).

In 2013 and 2019 nosocomial outbreaks caused by VIM-producing S. marcescens strains were reported at Argentina and Italy, respectively (Iovene et al., 2019; Nastro et al., 2013), the latter with a fatality rate of 50% (Iovene et al., 2019). Also, an outbreak associated with a strain producing IMP-4 and VIM-2 was documented in 2018 in Egypt (Ghaith et al., 2018). In 2020, Toth et al. (2020) isolated a VIM-4 producing S. marcescens from a Hungarian patient with no history of carbapenem treatment. While in 2021 in China Huang et al. (2021) recovered a carbapenem-resistant strain from a patient with asymptomatic bacteriuria, the resistant phenotype was associated with production of IMP-4 from a conjugative plasmid. A multi-resistant S. marcescens isolate carrying both genes blaIMP-26 and mcr-9 within the IncHI2/2A megaplasmid was isolated during 2022 in China (Zhong et al., 2022).

Plasmid-encoded ribosomal methyltranferases and aminoglycoside modifying enzymes

Ribosomal protection through methylation of 16S rRNA has been described as a principal mechanism of aminoglycoside resistance. Activity of 16S rRNA methylases confer high levels of aminoglycoside resistance however, as mentioned before most S. marcescens isolates remain susceptible to aminoglycosides with resistance predominantly through acquired means. Accordingly, S. marcescens S-95, an isolate from Japan encoding a new 16S rRNA methylase referred as RmtB displayed an unusual high degree of resistance to several aminoglycosides including kanamycin, tobramycin, amikacin, arbekacin, gentamicin, sisomicin, and isepamicin (Doi et al., 2004). Gene rmtB was found within a nonconjugative large plasmid also carryng the right end of transposon Tn3, including TEM-1 (Doi et al., 2004). RmtB shares 82% identity with the plasmid-encoded methylase, RmtA from P. aeruginosa. Consequently, its assumed that both genes have been mobilized by horizontal gene transfer in these pathogens.

On the other hand, prevalence of S. marcescens strains carrying conjugative plasmids encoding the AME enzyme AAC(6′), was reported in amikacin-resistant strains from three different cities in the U.S. evidencing that chromosomal encoded AAC(6′)-1 commonly coexists with homologues enzymes encoded by plasmids (John Jr et al., 1982). In addition, a novel aminoglycoside resistant gene, ant(3″)-Ii-aac(6′)-IId encoding an enzyme catalyzing bifunctional activities (adenylation and acetylation), was found in a 60-kb conjugative plasmid in S. marcescens SCH909 isolated in Greece (Centron & Roy, 2002). In this ANT(3′)-Ii/AAC(6′)-IId enzyme, adenyltransferase domain is highly specific to streptomycin and spectinomycin while the acetyltransferase domain displays a broader substrate range (Kim et al., 2006). APH(3′)-VIa is the only APH enzyme described in S. marcescens, the gene aph(3′)-VIa was found in plasmid R478 with a prevalence of 20% of the S. marcescens isolates from an Argentinian hospital (Garcia et al., 1996; Gilmour et al., 2004).

Conclusions

S. marcescens is an ubiquitous microorganism which has gained recognition as an important opportunistic pathogen during last decades. In clinical practice, clearance of S. marcescens infections is challenging, largely because the immunological features of it most common hosts (newborns and immunocompromised individuals), but also because the wide repertoire of intrinsic antibiotic resistance determinants and resilience capacity displayed by S. marcescens strains, which narrow drug therapy opportunities and treatment success.

In this review, we aimed to compile our current knowledge of the mechanisms associated with the multidrug resistance phenotype of S. marcescens. To highlight, intrinsic elements of the RND along with MFS efflux pumps seem to confer the greatest range activity against antibiotics and toxic compounds. The AmpC activity is also responsibly of resistance to different penicillins, while its up-regulation might confer extended spectrum cephalosporins resistance. Moreover, plasmid-encoded carbapenemases (OXA, IMP, VIM and KPC) are sporadically reported in nosocomial S. marcescens strains. Prevalence of these carbapenemases among multi-drug resistant pathogens is a major concern. Thus, their continuous monitoring is critical in order to prevent wider spread of the mobile elements encoding this enzymes. Future studies evaluating contribution of other S. marcescens efflux systems, including SMR and MATE efflux pumps, along with regulatory mechanisms promoting adaptive resistance in this bacterium and how it can interact synergistically with intrinsic and acquired mechanisms are warranted.

Neglected use of antibiotics is considered a main driver of bacterial resistance, nonetheless, for some ubiquitous species (as several Serratia genus members), their long coevolution with natural antibacterial compounds has derived in defined patterns of drug tolerance/resistance. We also highlight here the complexity to distinguish and define S. marcescens nosocomial from environmental strains, and its potential as a natural reservoir of antimicrobial resistance elements.

Finally, human activities as environmental pollution and climate change are indirect drivers and stressors that might contribute to the emergence of resistant phenotypes. Hence, to obtain genetic information about taxonomic relatives of opportunistic pathogens and modulation of their genomes during natural interactions or after niche alterations might aid to elaborate mitigation plans to prevent future pathogenic outbreaks.

Funding Statement

This work was supported by two grants from the Consejo Nacional de Ciencia y Tecnología (CONACyT): CF-2019/15020 to Faviola Tavares-Carreón and CF-2019/40760 to Angel Andrade. Karla D. Anda-Mora is supported by a doctoral research scholarship from CONACyT (No. 1004858). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Additional Information and Declarations

Competing Interests

The authors declare there are no competing interests.

Author Contributions

Faviola Tavares-Carreon conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Karla De Anda-Mora performed the experiments, prepared figures and/or tables, and approved the final draft.

Idalia C. Rojas-Barrera performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

Angel Andrade performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

There is no data to publish; this article is a literature review.

References

  • Adeolu et al. (2016).Adeolu M, Alnajar S, Naushad S, SG R. Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov. Pectobacteriaceae fam. nov. Yersiniaceae fam. nov. Hafniaceae fam. nov. Morganellaceae fam. nov. and Budviciaceae fam. nov. International Journal of Systematic and Evolutionary Microbiology. 2016;66:5575–5599. doi: 10.1099/ijsem.0.001485. [DOI] [PubMed] [Google Scholar]
  • Ball, McGhie & Geddes (1977).Ball AP, McGhie D, Geddes AM. Serratia marcescens in a general hospital. Quarterly Journal of Medicine. 1977;46:63–71. [PubMed] [Google Scholar]
  • Baranova & Nikaido (2002).Baranova N, Nikaido H. The baeSR two-component regulatory system activates transcription of the yegMNOB (mdtABCD) transporter gene cluster in Escherichia coli and increases its resistance to novobiocin and deoxycholate. Journal of Bacteriology. 2002;184:4168–4176. doi: 10.1128/JB.184.15.4168-4176.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Barchiesi et al. (2012).Barchiesi J, Castelli ME, Di Venanzio G, Colombo MI, Garcia Vescovi E. The PhoP/PhoQ system and its role in Serratia marcescens pathogenesis. Journal of Bacteriology. 2012;194:2949–2961. doi: 10.1128/JB.06820-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Baron et al. (2016).Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin resistance: knowns and unknowns. International Journal of Antimicrobial Agents. 2016;48:583–591. doi: 10.1016/j.ijantimicag.2016.06.023. [DOI] [PubMed] [Google Scholar]
  • Begic & Worobec (2008).Begic S, Worobec EA. The role of the Serratia marcescens SdeAB multidrug efflux pump and TolC homologue in fluoroquinolone resistance studied via gene-knockout mutagenesis. Microbiology. 2008;154:454–461. doi: 10.1099/mic.0.2007/012427-0. [DOI] [PubMed] [Google Scholar]
  • Bertrand & Dowzicky (2012).Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline evaluation and surveillance trial. Clinical Therapeutics. 2012;34:124–137. doi: 10.1016/j.clinthera.2011.11.023. [DOI] [PubMed] [Google Scholar]
  • Blair et al. (2015).Blair JM, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathfer U, Ruggerone P, Vargiu AV, Baylay AJ, Smith HE, Brandon Y, Galloway D, Piddock LJ. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:3511–3516. doi: 10.1073/pnas.1419939112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Blanco et al. (2016).Blanco P, Hernando-Amado S, Reales-Calderón JA, Corona F, Lira F, Alcalde-Rico M, Bernardini A, Sánchez MB, Martínez JL. Bacterial multidrug efflux pumps: much more than antibiotic resistance determinants. Microorganisms. 2016;4:14. doi: 10.3390/microorganisms4010014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bolourchi et al. (2022).Bolourchi N, Noori Goodarzi N, Giske CG, Nematzadeh S, Haririzadeh Jouriani F, Solgi H, Badmasti F. Comprehensive pan-genomic, resistome and virulome analysis of clinical OXA-48 producing carbapenem-resistant Serratia marcescens strains. Gene. 2022;822:146355. doi: 10.1016/j.gene.2022.146355. [DOI] [PubMed] [Google Scholar]
  • Boyd et al. (2020).Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-beta-Lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrobial Agents and Chemotherapy. 2020;64:e00397-20. doi: 10.1128/AAC.00397-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Cai et al. (2008).Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrobial Agents and Chemotherapy. 2008;52:2014–2018. doi: 10.1128/AAC.01539-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Carrer et al. (2008).Carrer A, Poirel L, Pitout JD, Church D, Nordmann P. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada. International Journal of Antimicrobial Agents. 2008;31:181–182. doi: 10.1016/j.ijantimicag.2007.10.007. [DOI] [PubMed] [Google Scholar]
  • Casolari et al. (2005).Casolari C, Pecorari M, Fabio G, Cattani S, Venturelli C, Piccinini L, Tamassia MG, Gennari W, Sabbatini AM, Leporati G, Marchegiano P, Rumpianesi F, Ferrari F. A simultaneous outbreak of Serratia marcescens and Klebsiella pneumoniae in a neonatal intensive care unit. Journal of Hospital Infection. 2005;61:312–320. doi: 10.1016/j.jhin.2005.03.005. [DOI] [PubMed] [Google Scholar]
  • Cayo et al. (2017).Cayo R, Leme RC, Streling AP, Matos AP, Nodari CS, Chaves JR, Brandao JL, De Almeida MF, Carrareto V, De Castro Pereira MA, De Almeida JP, Ferreira DC, Gales AC. Serratia marcescens harboring SME-4 in Brazil: a silent threat. Diagnostic Microbiology and Infectious Disease. 2017;87:357–358. doi: 10.1016/j.diagmicrobio.2017.01.008. [DOI] [PubMed] [Google Scholar]
  • Centron & Roy (2002).Centron D, Roy PH. Presence of a group II intron in a multiresistant Serratia marcescens strain that harbors three integrons and a novel gene fusion. Antimicrobial Agents and Chemotherapy. 2002;46:1402–1409. doi: 10.1128/AAC.46.5.1402-1409.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Chen et al. (2003a).Chen J, Kuroda T, Huda MN, Mizushima T, Tsuchiya T. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. Journal of Antimicrobial Chemotherapy. 2003a;52:176–179. doi: 10.1093/jac/dkg308. [DOI] [PubMed] [Google Scholar]
  • Chen et al. (2003b).Chen J, Lee EW, Kuroda T, Mizushima T, Tsuchiya T. Multidrug resistance in Serratia marcescens and cloning of genes responsible for the resistance. Biological and Pharmaceutical Bulletin. 2003b;26:391–393. doi: 10.1248/bpb.26.391. [DOI] [PubMed] [Google Scholar]
  • Chen et al. (2022).Chen L, Ai W, Zhou Y, Wu C, Guo Y, Wu X, Wang B, Rao L, Xu Y, Zhang J, Chen L, Yu F. Outbreak of IncX8 plasmid-Mediated KPC-3-Producing Enterobacterales infection, China. Emerging Infectious Diseases. 2022;28:1421–1430. doi: 10.3201/eid2807.212181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Choi et al. (2007).Choi SH, Lee JE, Park SJ, Kim MN, Choo EJ, Kwak YG, Jeong JY, Woo JH, Kim NJ, Kim YS. Prevalence, microbiology, and clinical characteristics of extended-spectrum b-lactamase-producing Enterobacter spp. Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea. European Journal of Clinical Microbiology and Infectious Diseases. 2007;26:557–561. doi: 10.1007/s10096-007-0308-2. [DOI] [PubMed] [Google Scholar]
  • Choi et al. (2008).Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN, Woo JH, Kim YS. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC b-lactamase: implications for antibiotic use. Antimicrobial Agents and Chemotherapy. 2008;52:995–1000. doi: 10.1128/AAC.01083-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Choudhury et al. (2014).Choudhury HG, Tong Z, Mathavan I, Li Y, Iwata S, Zirah S, Rebuffat S, Van Veen HW, Beis K. Structure of an antibacterial peptide ATP-binding cassette transporter in a novel outward occluded state. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:9145–9150. doi: 10.1073/pnas.1320506111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Chow et al. (1991).Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Annals of Internal Medicine. 1991;115:585–590. doi: 10.7326/0003-4819-115-8-585. [DOI] [PubMed] [Google Scholar]
  • Crowder, Spencer & Vila (2006).Crowder MW, Spencer J, Vila AJ. Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Accounts of Chemical Research. 2006;39:721–728. doi: 10.1021/ar0400241. [DOI] [PubMed] [Google Scholar]
  • David et al. (2006).David MD, Weller TM, Lambert P, Fraise AP. An outbreak of Serratia marcescens on the neonatal unit: a tale of two clones. Journal of Hospital Infection. 2006;63:27–33. doi: 10.1016/j.jhin.2005.11.006. [DOI] [PubMed] [Google Scholar]
  • Dawson & Locher (2006).Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature. 2006;443:180–185. doi: 10.1038/nature05155. [DOI] [PubMed] [Google Scholar]
  • De Ondarza (2017).De Ondarza J. Ozone sensitivity and catalase activity in pigmented and non-pigmented strains of Serratia Marcescens. Open Microbiology Journal. 2017;11:12–22. doi: 10.2174/1874285801711010012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Doi et al. (2004).Doi Y, Yokoyama K, Yamane K, Wachino J, Shibata N, Yagi T, Shibayama K, Kato H, Arakawa Y. Plasmid-mediated 16S rRNA methylase in Serratia marcescens conferring high-level resistance to aminoglycosides. Antimicrobial Agents and Chemotherapy. 2004;48:491–496. doi: 10.1128/AAC.48.2.491-496.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Du et al. (2018).Du D, Wang-Kan X, Neuberger A, Van Veen HW, Pos KM, Piddock LJV, Luisi BF. Multidrug efflux pumps: structure, function and regulation. Nature Reviews. Microbiology. 2018;16:523–539. doi: 10.1038/s41579-018-0048-6. [DOI] [PubMed] [Google Scholar]
  • Evans, Feola & Rapp (1999).Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. The Annals of Pharmacotherapy. 1999;33:960–967. doi: 10.1345/aph.18426. [DOI] [PubMed] [Google Scholar]
  • Ferreira et al. (2020).Ferreira RL, Rezende GS, Damas MSF, Oliveira-Silva M, Pitondo-Silva A, Brito MCA, Leonardecz E, De Goes FR, Campanini EB, Malavazi I, Da Cunha AF, Pranchevicius MDS. Characterization of KPC-Producing Serratia marcescens in an intensive care unit of a brazilian tertiary hospital. Frontiers in Microbiology. 2020;11:956. doi: 10.3389/fmicb.2020.00956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Firmo et al. (2020).Firmo EF, Beltrao EMB, Silva F, Alves LC, Brayner FA, Veras DL, Lopes ACS. Association of blaNDM-1 with blaKPC-2 and aminoglycoside-modifying enzyme genes among Klebsiella pneumoniae Proteus mirabilis and Serratia marcescens clinical isolates in Brazil. Journal of Global Antimicrobial Resistance. 2020;21:255–261. doi: 10.1016/j.jgar.2019.08.026. [DOI] [PubMed] [Google Scholar]
  • Fuste et al. (2012).Fuste E, Galisteo GJ, Jover L, Vinuesa T, Villa TG, Vinas M. Comparison of antibiotic susceptibility of old and current Serratia. Future Microbiology. 2012;7:781–786. doi: 10.2217/fmb.12.40. [DOI] [PubMed] [Google Scholar]
  • Gadea et al. (2017).Gadea R, Fernandez Fuentes MA, Perez Pulido R, Galvez A, Ortega E. Effects of exposure to quaternary-ammonium-based biocides on antimicrobial susceptibility and tolerance to physical stresses in bacteria from organic foods. Food Microbiology. 2017;63:58–71. doi: 10.1016/j.fm.2016.10.037. [DOI] [PubMed] [Google Scholar]
  • Gajdacs & Urban (2019).Gajdacs M, Urban E. Resistance trends and epidemiology of Citrobacter-Enterobacter-Serratia in urinary tract infections of inpatients and outpatients (RECESUTI): a 10-year survey. Medicina. 2019;55:285. doi: 10.3390/medicina55060285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Gales et al. (2001).Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC programme. Diagnostic Microbiology and Infectious Disease. 2001;39:125–127. doi: 10.1016/s0732-8893(00)00222-4. [DOI] [PubMed] [Google Scholar]
  • Garcia et al. (1996).Garcia DC, Catalano M, Pineiro S, Woloj M, Kaufman S, Sordelli DO. The emergence of resistance to amikacin in Serratia marcescens isolates from patients with nosocomial infection. International Journal of Antimicrobial Agents. 1996;7:203–210. doi: 10.1016/s0924-8579(96)00322-6. [DOI] [PubMed] [Google Scholar]
  • Ghaith et al. (2018).Ghaith DM, Zafer MM, Ismail DK, Al-Agamy MH, Bohol MFF, Al-Qahtani A, Al-Ahdal MN, Elnagdy SM, Mostafa IY. First reported nosocomial outbreak of Serratia marcescens harboring bla IMP-4 and bla VIM-2 in a neonatal intensive care unit in Cairo, Egypt. Infection and Drug Resistance. 2018;11:2211–2217. doi: 10.2147/IDR.S174869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Gilmour et al. (2004).Gilmour MW, Thomson NR, Sanders M, Parkhill J, Taylor DE. The complete nucleotide sequence of the resistance plasmid R478: defining the backbone components of incompatibility group H conjugative plasmids through comparative genomics. Plasmid. 2004;52:182–202. doi: 10.1016/j.plasmid.2004.06.006. [DOI] [PubMed] [Google Scholar]
  • Greco-Stewart et al. (2012).Greco-Stewart VS, Brown EE, Parr C, Kalab M, Jacobs MR, Yomtovian RA, Ramirez-Arcos SM. Serratia marcescens strains implicated in adverse transfusion reactions form biofilms in platelet concentrates and demonstrate reduced detection by automated culture. Vox Sanguinis. 2012;102:212–220. doi: 10.1111/j.1423-0410.2011.01550.x. [DOI] [PubMed] [Google Scholar]
  • Grimont, Grimont & De Rosnay (1977).Grimont PA, Grimont F, De Rosnay HL. Taxonomy of the genus Serratia. Journal of General Microbiology. 1977;98:39–66. doi: 10.1099/00221287-98-1-39. [DOI] [PubMed] [Google Scholar]
  • Gunn et al. (1998).Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Molecular Microbiology. 1998;27:1171–1182. doi: 10.1046/j.1365-2958.1998.00757.x. [DOI] [PubMed] [Google Scholar]
  • Hasan, Dutta & Nguyen (2021).Hasan CM, Dutta D, Nguyen ANT. Revisiting antibiotic resistance: mechanistic foundations to evolutionary outlook. Antibiotics. 2021;11:40. doi: 10.3390/antibiotics11010040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Hernando-Amado et al. (2016).Hernando-Amado S, Blanco P, Alcalde-Rico M, Corona F, Reales-Calderon JA, Sanchez MB, Martinez JL. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. Drug Resistance Updates. 2016;28:13–27. doi: 10.1016/j.drup.2016.06.007. [DOI] [PubMed] [Google Scholar]
  • Hidri et al. (2005).Hidri N, Barnaud G, Decré D, Cerceau C, Lalande V, Petit JC, Labia R, Arlet G. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC b-lactamase of a Serratia marcescens clinical isolate. Journal of Antimicrobial Chemotherapy. 2005;55:496–499. doi: 10.1093/jac/dki025. [DOI] [PubMed] [Google Scholar]
  • Hornsey et al. (2010).Hornsey M, Ellington MJ, Doumith M, Hudson S, Livermore DM, Woodford N. Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. Journal of Antimicrobial Chemotherapy. 2010;65:479–482. doi: 10.1093/jac/dkp475. [DOI] [PubMed] [Google Scholar]
  • Huang et al. (2021).Huang X, Shen S, Shi Q, Ding L, Wu S, Han R, Zhou X, Yu H, Hu F. First report of bla IMP-4 and bla SRT-2 coproducing Serratia marcescens clinical isolate in China. Frontiers in Microbiology. 2021;12:743312. doi: 10.3389/fmicb.2021.743312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Iguchi et al. (2014).Iguchi A, Nagaya Y, Pradel E, Ooka T, Ogura Y, Katsura K, Kurokawa K, Oshima K, Hattori M, Parkhill J, Sebaihia M, Coulthurst SJ, Gotoh N, Thomson NR, Ewbank JJ, Hayashi T. Genome evolution and plasticity of Serratia marcescens, an important multidrug-resistant nosocomial pathogen. Genome Biology and Evolution. 2014;6:2096–2110. doi: 10.1093/gbe/evu160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Iovene et al. (2019).Iovene MR, Pota V, Galdiero M, Corvino G, Di Lella FM, Stelitano D, Passavanti MB, Pace MC, Alfieri A, Di Franco S, Aurilio C, Sansone P, Niyas VKM, Fiore M. First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August-2018: a case report and literature review. World Journal of Clinical Cases. 2019;7:3535–3548. doi: 10.12998/wjcc.v7.i21.3535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Jacoby (2009).Jacoby GA. AmpC beta-lactamases. Clinical Microbiology Reviews. 2009;22:161–182. doi: 10.1128/CMR.00036-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Joris et al. (1986).Joris B, De Meester F, Galleni M, Masson S, Dusart J, Frere JM, Van Beeumen J, Bush K, Sykes R. Properties of a class C beta-lactamase from Serratia marcescens. Biochemical Journal. 1986;239:581–586. doi: 10.1042/bj2390581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • John Jr et al. (1982).John Jr JF, McNeill WF, Price KE, Kresel PA. Evidence for a chromosomal site specifying amikacin resistance in multiresistant Serratia marcescens. Antimicrobial Agents and Chemotherapy. 1982;21:587–591. doi: 10.1128/AAC.21.4.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Kim et al. (2006).Kim C, Hesek D, Zajicek J, Vakulenko SB, Mobashery S. Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3′)-Ii/AAC(6′)-IId from Serratia marcescens. Biochemistry. 2006;45:8368–8377. doi: 10.1021/bi060723g. [DOI] [PubMed] [Google Scholar]
  • Kohlmann, Bähr & Gatermann (2018).Kohlmann R, Bähr T, Gatermann SG. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC b-lactamase. Journal of Antimicrobial Chemotherapy. 2018;73:1530–1536. doi: 10.1093/jac/dky084. [DOI] [PubMed] [Google Scholar]
  • Korner et al. (1994).Korner RJ, Nicol A, Reeves DS, MacGowan AP, Hows J. Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin’s lymphoma. Journal of Infection. 1994;29:73–76. doi: 10.1016/s0163-4453(94)95141-1. [DOI] [PubMed] [Google Scholar]
  • Kumar & Worobec (2005).Kumar A, Worobec EA. Cloning, sequencing, and characterization of the SdeAB multidrug efflux pump of Serratia marcescens. Antimicrobial Agents and Chemotherapy. 2005;49:1495–1501. doi: 10.1128/AAC.49.4.1495-1501.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lamotte-Brasseur et al. (1994).Lamotte-Brasseur J, Knox J, Kelly JA, Charlier P, Fonze E, Dideberg O, Frere JM. The structures and catalytic mechanisms of active-site serine beta-lactamases. Biotechnology and Genetic Engineering Reviews. 1994;12:189–230. doi: 10.1080/02648725.1994.10647912. [DOI] [PubMed] [Google Scholar]
  • Lin et al. (2014a).Lin QY, Tsai YL, Liu MC, Lin WC, Hsueh PR, Liaw SJ. Serratia marcescens arn, a PhoP-regulated locus necessary for polymyxin B resistance. Antimicrobial Agents and Chemotherapy. 2014a;58:5181–5190. doi: 10.1128/AAC.00013-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lin et al. (2014b).Lin YT, Huang YW, Liou RS, Chang YC, Yang TC. MacABCsm, an ABC-type tripartite efflux pump of Stenotrophomonas maltophilia involved in drug resistance, oxidative and envelope stress tolerances and biofilm formation. Journal of Antimicrobial Chemotherapy. 2014b;69:3221–3226. doi: 10.1093/jac/dku317. [DOI] [PubMed] [Google Scholar]
  • Mahlen (2011).Mahlen SD. Serratia infections: from military experiments to current practice. Clinical Microbiology Reviews. 2011;24:755–791. doi: 10.1128/CMR.00017-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Mahlen et al. (2003).Mahlen SD, Morrow SS, Abdalhamid B, Hanson ND. Analyses of ampC gene expression in Serratia marcescens reveal new regulatory properties. Journal of Antimicrobial Chemotherapy. 2003;51:791–802. doi: 10.1093/jac/dkg133. [DOI] [PubMed] [Google Scholar]
  • Mammeri et al. (2004).Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC b-lactamase of a Serratia marcescens clinical isolate. Antimicrobial Agents and Chemotherapy. 2004;48:716–720. doi: 10.1128/AAC.48.3.716-720.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Marquez (2005).Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie. 2005;87:1137–1147. doi: 10.1016/j.biochi.2005.04.012. [DOI] [PubMed] [Google Scholar]
  • Maseda et al. (2009).Maseda H, Hashida Y, Konaka R, Shirai A, Kourai H. Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens. Antimicrobial Agents and Chemotherapy. 2009;53:5230–5235. doi: 10.1128/AAC.00631-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Matsuo et al. (2008).Matsuo T, Chen J, Minato Y, Ogawa W, Mizushima T, Kuroda T, Tsuchiya T. SmdAB, a heterodimeric ABC-Type multidrug efflux pump, in Serratia marcescens. Journal of Bacteriology. 2008;190:648–654. doi: 10.1128/JB.01513-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Matteoli et al. (2021).Matteoli FP, Pedrosa-Silva F, Dutra-Silva L, Giachini AJ. The global population structure and beta-lactamase repertoire of the opportunistic pathogen Serratia marcescens. Genomics. 2021;113:3523–3532. doi: 10.1016/j.ygeno.2021.08.009. [DOI] [PubMed] [Google Scholar]
  • Miao et al. (2019).Miao M, Wen H, Xu P, Niu S, Lv J, Xie X, Mediavilla JR, Tang YW, Kreiswirth BN, Zhang X, Zhang H, Du H, Chen L. Genetic diversity of Carbapenem-Resistant Enterobacteriaceae (CRE) clinical isolates from a tertiary hospital in eastern China. Frontiers in Microbiology. 2019;9:3341. doi: 10.3389/fmicb.2018.03341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Mima et al. (2009).Mima T, Kohira N, Li Y, Sekiya H, Ogawa W, Kuroda T, Tsuchiya T. Gene cloning and characteristics of the RND-type multidrug efflux pump MuxABC-OpmB possessing two RND components in Pseudomonas aeruginosa. Microbiology. 2009;155:3509–3517. doi: 10.1099/mic.0.031260-0. [DOI] [PubMed] [Google Scholar]
  • Minato et al. (2008).Minato Y, Shahcheraghi F, Ogawa W, Kuroda T, Tsuchiya T. Functional gene cloning and characterization of the SsmE multidrug efflux pump from Serratia marcescens. Biological and Pharmaceutical Bulletin. 2008;31:516–519. doi: 10.1248/bpb.31.516. [DOI] [PubMed] [Google Scholar]
  • Naas et al. (1994).Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrobial Agents and Chemotherapy. 1994;38:1262–1270. doi: 10.1128/AAC.38.6.1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Nastro et al. (2013).Nastro M, Monge R, Zintgraff J, Vaulet LG, Boutureira M, Famiglietti A, Rodriguez CH. First nosocomial outbreak of VIM-16-producing Serratia marcescens in Argentina. Clinical Microbiology and Infection. 2013;19:617–619. doi: 10.1111/j.1469-0691.2012.03978.x. [DOI] [PubMed] [Google Scholar]
  • Neuberger, Du & Luisi (2018).Neuberger A, Du D, Luisi BF. Structure and mechanism of bacterial tripartite efflux pumps. Research in Microbiology. 2018;169:401–413. doi: 10.1016/j.resmic.2018.05.003. [DOI] [PubMed] [Google Scholar]
  • Nishino et al. (2003).Nishino K, Yamada J, Hirakawa H, Hirata T, Yamaguchi A. Roles of TolC-dependent multidrug transporters of Escherichia coli in resistance to beta-lactams. Antimicrobial Agents and Chemotherapy. 2003;47:3030–3033. doi: 10.1128/AAC.47.9.3030-3033.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Olaitan et al. (2014a).Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, Thongmalayvong B, Akkhavong K, Somphavong S, Paboriboune P, Chaisiri K, Komalamisra C, Adelowo OO, Fagade OE, Banjo OA, Oke AJ, Adler A, Assous MV, Morand S, Raoult D, Rolain JM. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study. International Journal of Antimicrobial Agents. 2014a;44:500–507. doi: 10.1016/j.ijantimicag.2014.07.020. [DOI] [PubMed] [Google Scholar]
  • Olaitan, Morand & Rolain (2014b).Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Frontiers in Microbiology. 2014b;5:643–641. doi: 10.3389/fmicb.2014.00643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Pao, Paulsen & Saier Jr (1998).Pao SS, Paulsen IT, Saier Jr MH. Major facilitator superfamily. Microbiology and Molecular Biology Reviews. 1998;62:1–34. doi: 10.1128/MMBR.62.1.1-34.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Perez-Viso et al. (2021).Perez-Viso B, Hernandez-Garcia M, Ponce-Alonso M, Morosini MI, Ruiz-Garbajosa P, Del Campo R, Canton R. Characterization of carbapenemase-producing Serratia marcescens and whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016-18) Journal of Antimicrobial Chemotherapy. 2021;76:110–116. doi: 10.1093/jac/dkaa398. [DOI] [PubMed] [Google Scholar]
  • Peschel (2002).Peschel A. How do bacteria resist human antimicrobial peptides? Trends in Microbiology. 2002;10:179–186. doi: 10.1016/S0966-842X(02)02333-8. [DOI] [PubMed] [Google Scholar]
  • Poirel et al. (2007).Poirel L, Wenger A, Bille J, Bernabeu S, Naas T, Nordmann P. SME-2-producing Serratia marcescens isolate from Switzerland. Antimicrobial Agents and Chemotherapy. 2007;51:2282–2283. doi: 10.1128/AAC.00309-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Queenan et al. (2006).Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrobial Agents and Chemotherapy. 2006;50:3485–3487. doi: 10.1128/AAC.00363-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Queenan et al. (2000).Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC, Quinn JP, Hindler J, Medeiros AA, Bush K. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrobial Agents and Chemotherapy. 2000;44:3035–3039. doi: 10.1128/AAC.44.11.3035-3039.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Ramirez & Tolmasky (2010).Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resistance Updates. 2010;13:151–171. doi: 10.1016/j.drup.2010.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Redondo-Bravo et al. (2019).Redondo-Bravo L, Gutierrez-Gonzalez E, San Juan-Sanz I, Fernandez-Jimenez I, Ruiz-Carrascoso G, Gallego-Lombardo S, Sanchez-Garcia L, Elorza-Fernandez D, Pellicer-Martinez A, Omenaca F, Robustillo-Rodela A. Serratia marcescens outbreak in a neonatology unit of a Spanish tertiary hospital: risk factors and control measures. American Journal of Infection Control. 2019;47:271–279. doi: 10.1016/j.ajic.2018.08.026. [DOI] [PubMed] [Google Scholar]
  • Sader et al. (2014).Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011) Diagnostic Microbiology and Infectious Disease. 2014;78:443–448. doi: 10.1016/j.diagmicrobio.2013.11.025. [DOI] [PubMed] [Google Scholar]
  • Sanchez et al. (1997).Sanchez L, Ruiz N, Leranoz S, Vinas M, Puig M. The role of outer membrane in Serratia marcescens intrinsic resistance to antibiotics. Microbiologia. 1997;13:315–320. [PubMed] [Google Scholar]
  • Sandner-Miranda et al. (2018).Sandner-Miranda L, Vinuesa P, Cravioto A, Morales-Espinosa R. The genomic basis of intrinsic and acquired antibiotic resistance in the genus Serratia. Frontiers in Microbiology. 2018;9:828. doi: 10.3389/fmicb.2018.00828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Saralegui et al. (2020).Saralegui C, Ponce-Alonso M, Perez-Viso B, Moles Alegre L, Escribano E, Lazaro-Perona F, Lanza VF, De Pipaon MS, Rodriguez JM, Baquero F, Del Campo R. Genomics of Serratia marcescens isolates causing outbreaks in the same pediatric unit 47 years apart: position in an updated phylogeny of the species. Frontiers in Microbiology. 2020;11:451. doi: 10.3389/fmicb.2020.00451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Schmidtke & Hanson (2006).Schmidtke AJ, Hanson ND. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance. Antimicrobial Agents and Chemotherapy. 2006;50:2030–2037. doi: 10.1128/AAC.01458-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Shahcheraghi et al. (2007).Shahcheraghi F, Minato Y, Chen J, Mizushima T, Ogawa W, Kuroda T, Tsuchiya T. Molecular cloning and characterization of a multidrug efflux pump, SmfY, from Serratia marcescens. Biological and Pharmaceutical Bulletin. 2007;30:798–800. doi: 10.1248/bpb.30.798. [DOI] [PubMed] [Google Scholar]
  • Shaw et al. (1992).Shaw KJ, Rather PN, Sabatelli FJ, Mann P, Munayyer H, Mierzwa R, Petrikkos GL, Hare RS, Miller GH, Bennett P, Downey P. Characterization of the chromosomal aac(6′)-Ic gene from Serratia marcescens. Antimicrobial Agents and Chemotherapy. 1992;36:1447–1455. doi: 10.1128/AAC.36.7.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Sheinman et al. (2021).Sheinman M, Arkhipova K, Arndt PF, Dutilh BE, Hermsen R, Massip F. Identical sequences found in distant genomes reveal frequent horizontal transfer across the bacterial domain. Elife. 2021;10:e62719. doi: 10.7554/eLife.62719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Shirshikova et al. (2021).Shirshikova TV, Sierra-Bakhshi CG, Kamaletdinova LK, Matrosova LE, Khabipova NN, Evtugyn VG, Khilyas IV, Danilova IV, Mardanova AM, Sharipova MR, Bogomolnaya LM. The ABC-Type Efflux Pump MacAB is involved in protection of Serratia marcescens against aminoglycoside antibiotics, polymyxins, and oxidative stress. MSphere. 2021;6:e00033-21. doi: 10.1128/mSphere.00033-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Sidjabat et al. (2009).Sidjabat HE, Silveira FP, Potoski BA, Abu-Elmagd KM, Adams-Haduch JM, Paterson DL, Doi Y. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clinical Infectious Diseases. 2009;49:1736–1738. doi: 10.1086/648077. [DOI] [PubMed] [Google Scholar]
  • Siedner et al. (2014).Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O’Brien TF, Marty FM. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clinical Infectious Diseases. 2014;58:1554–1563. doi: 10.1093/cid/ciu182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Su et al. (2003).Su LH, Ou JT, Leu HS, Chiang PC, Chiu YP, Chia JH, Kuo AJ, Chiu CH, Chu C, Wu TL, Sun CF, Riley TV, Chang BJ, Infection Control G. Extended epidemic of nosocomial urinary tract infections caused by Serratia marcescens. Journal of Clinical Microbiology. 2003;41:4726–4732. doi: 10.1128/JCM.41.10.4726-4732.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Suh et al. (2010).Suh B, Bae IK, Kim J, Jeong SH, Yong D, Lee K. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC b-lactamase overproduction and outer membrane protein loss. Antimicrobial Agents and Chemotherapy. 2010;54:5057–5061. doi: 10.1128/AAC.00768-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Tal & Schuldiner (2009).Tal N, Schuldiner S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:9051–9056. doi: 10.1073/pnas.0902400106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Tamma et al. (2022).Tamma PD AS, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious diseases society of America guidance on the treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. 2022. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/ [06 September 2022]. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/ [DOI] [PubMed]
  • Tamma et al. (2013).Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. The use of cefepime for treating AmpC b-lactamase-producing Enterobacteriaceae. Clinical Infectious Diseases. 2013;57:781–788. doi: 10.1093/cid/cit395. [DOI] [PubMed] [Google Scholar]
  • Thompson et al. (2007).Thompson SA, Maani EV, Lindell AH, King CJ, McArthur JV. Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens. Applied and Environmental Microbiology. 2007;73:2199–2206. doi: 10.1128/AEM.02511-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Toba et al. (2019).Toba S, Minato Y, Kondo Y, Hoshikawa K, Minagawa S, Komaki S, Kumagai T, Matoba Y, Morita D, Ogawa W, Gotoh N, Tsuchiya T, Kuroda T. Comprehensive analysis of resistance-nodulation-cell division superfamily (RND) efflux pumps from Serratia marcescens, Db10. Scientific Reports. 2019;9:4854. doi: 10.1038/s41598-019-41237-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Toth et al. (2020).Toth A, Makai A, Janvari L, Damjanova I, Gajdacs M, Urban E. Characterization of a rare bla VIM-4 metallo-beta-lactamase-producing Serratia marcescens clinical isolate in Hungary. Heliyon. 2020;6:e04231. doi: 10.1016/j.heliyon.2020.e04231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Traub (2000).Traub WH. Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens. Chemotherapy. 2000;46:315–321. doi: 10.1159/000007304. [DOI] [PubMed] [Google Scholar]
  • Tsakris et al. (2010).Tsakris A, Voulgari E, Poulou A, Kimouli M, Pournaras S, Ranellou K, Kosmopoulou O, Petropoulou D. In vivo acquisition of a plasmid-mediated bla(KPC-2) gene among clonal isolates of Serratia marcescens. Journal of Clinical Microbiology. 2010;48:2546–2549. doi: 10.1128/JCM.00264-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Vadlamani et al. (2015).Vadlamani G, Thomas MD, Patel TR, Donald LJ, Reeve TM, Stetefeld J, Standing KG, Vocadlo DJ, Mark BL. The b-lactamase gene regulator AmpR is a tetramer that recognizes and binds the D-Ala-D-Ala motif of its repressor UDP-N-acetylmuramic acid (MurNAc)-pentapeptide. Journal of Biological Chemistry. 2015;290:2630–2643. doi: 10.1074/jbc.M114.618199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Velkov et al. (2016).Velkov T, Roberts KD, Thompson PE, Li J. Polymyxins: a new hope in combating Gram-negative superbugs? Future Medicinal Chemistry. 2016;8:1017–1025. doi: 10.4155/fmc-2016-0091. [DOI] [PubMed] [Google Scholar]
  • Venter et al. (2015).Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Frontiers in Microbiology. 2015;6:377. doi: 10.3389/fmicb.2015.00377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Vinogradov et al. (2006).Vinogradov E, Lindner B, Seltmann G, Radziejewska-Lebrecht J, Holst O. Lipopolysaccharides from Serratia marcescens possess one or two 4-amino-4-deoxy-L-arabinopyranose 1-phosphate residues in the lipid A and D-glycero-D-talo-oct-2-ulopyranosonic acid in the inner core region. Chemistry. 2006;12:6692–6700. doi: 10.1002/chem.200600186. [DOI] [PubMed] [Google Scholar]
  • Voelz et al. (2010).Voelz A, Muller A, Gillen J, Le C, Dresbach T, Engelhart S, Exner M, Bates CJ, Simon A. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. International Journal of Hygiene and Environmental Health. 2010;213:79–87. doi: 10.1016/j.ijheh.2009.09.003. [DOI] [PubMed] [Google Scholar]
  • Vonberg et al. (2011).Vonberg RP, Weitzel-Kage D, Behnke M, Gastmeier P. Worldwide Outbreak Database: the largest collection of nosocomial outbreaks. Infection. 2011;39:29–34. doi: 10.1007/s15010-010-0064-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wand et al. (2019).Wand ME, Jamshidi S, Bock LJ, Rahman KM, Sutton JM. SmvA is an important efflux pump for cationic biocides in Klebsiella pneumoniae and other Enterobacteriaceae. Scientific Reports. 2019;9:1344. doi: 10.1038/s41598-018-37730-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wang et al. (2022).Wang X, Xiao W, Li L, Jing M, Sun M, Chang Y, Qu Y, Jiang Y, Xu Q. Analysis of the molecular characteristics of a blaKPC-2-harbouring untypeable plasmid in Serratia marcescens. International Microbiology. 2022;25:237–244. doi: 10.1007/s10123-021-00172-2. [DOI] [PubMed] [Google Scholar]
  • WHO (2017).WHO WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
  • Wisplinghoff et al. (2004).Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases. 2004;39:309–317. doi: 10.1086/421946. [DOI] [PubMed] [Google Scholar]
  • Zhang et al. (2007).Zhang R, Zhou HW, Cai JC, Chen GX. Plasmid-mediated carbapenem-hydrolysing beta-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou, China. Journal of Antimicrobial Chemotherapy. 2007;59:574–576. doi: 10.1093/jac/dkl541. [DOI] [PubMed] [Google Scholar]
  • Zhong et al. (2022).Zhong Y, Liu W, Yuan P, Yang L, Xu Z, Chen D. Occurrence of Serratia marcescens carrying blaIMP-26 and mcr-9 in Southern China: new insights in the evolution of megaplasmid IMP-26. Antibiotics. 2022;11:869. doi: 10.3390/antibiotics11070869. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The following information was supplied regarding data availability:

There is no data to publish; this article is a literature review.


Articles from PeerJ are provided here courtesy of PeerJ, Inc

RESOURCES